newsfilter
← Latest News
GlobeNewswire·

Homology Medicines Reports Third Quarter 2022 Financial Results and Recent Highlights

- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted Albert Seymour, Ph.D., to Chief Executive Officer Driving